Cyclacel Pharmaceuticals (FRA:UXI) Total Liabilities : €7.52 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Cyclacel Pharmaceuticals Total Liabilities?

Cyclacel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was €7.52 Mil.

Cyclacel Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2023 (€6.29 Mil) to Sep. 2023 (€7.68 Mil) but then declined from Sep. 2023 (€7.68 Mil) to Dec. 2023 (€7.52 Mil).

Cyclacel Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€4.82 Mil) to Dec. 2022 (€7.19 Mil) and increased from Dec. 2022 (€7.19 Mil) to Dec. 2023 (€7.52 Mil).

Cyclacel Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Total Liabilities Chart

Cyclacel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3.25

2.91

4.82

7.19

7.52

Cyclacel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															7.19	6.93	6.29	7.68	7.52

Cyclacel Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cyclacel Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.484	+	(0.034	+	-1.942890293094E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	7.52

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	8.074	-	0.557
	=	7.52

Cyclacel Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.484	+	(0.034	+	-1.942890293094E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	7.52

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	8.074	-	0.557
	=	7.52

Cyclacel Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals (FRA:UXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (FRA:UXI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CYCCP.PFD:USA CYCC:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (FRA:UXI) Headlines

No Headlines